Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside

PCSK9 可欣 前蛋白转化酶 医学 阿利罗库单抗 癌症 胰腺癌 Evolocumab公司 从长凳到床边 生物信息学 癌症预防 低密度脂蛋白受体 胆固醇 内科学 生物 脂蛋白 载脂蛋白A1 医学物理学
作者
Xuhui Bao,Yongjun Liang,Hanman Chang,Tianji Cai,Baijie Feng,Konstantin B. Gordon,Yuekun Zhu,Hailian Shi,Yundong He,Liyi Xie
出处
期刊:Signal Transduction and Targeted Therapy [Springer Nature]
卷期号:9 (1): 13-13 被引量:194
标识
DOI:10.1038/s41392-023-01690-3
摘要

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related cardiovascular diseases (CVD). This comprehensive review delineates the intricate roles and wide-ranging implications of PCSK9, extending beyond CVD to emphasize its significance in diverse physiological and pathological states, including liver diseases, infectious diseases, autoimmune disorders, and notably, cancer. Our exploration offers insights into the interaction between PCSK9 and low-density lipoprotein receptors (LDLRs), elucidating its substantial impact on cholesterol homeostasis and cardiovascular health. It also details the evolution of PCSK9-targeted therapies, translating foundational bench discoveries into bedside applications for optimized patient care. The advent and clinical approval of innovative PCSK9 inhibitory therapies (PCSK9-iTs), including three monoclonal antibodies (Evolocumab, Alirocumab, and Tafolecimab) and one small interfering RNA (siRNA, Inclisiran), have marked a significant breakthrough in cardiovascular medicine. These therapies have demonstrated unparalleled efficacy in mitigating hypercholesterolemia, reducing cardiovascular risks, and have showcased profound value in clinical applications, offering novel therapeutic avenues and a promising future in personalized medicine for cardiovascular disorders. Furthermore, emerging research, inclusive of our findings, unveils PCSK9's potential role as a pivotal indicator for cancer prognosis and its prospective application as a transformative target for cancer treatment. This review also highlights PCSK9's aberrant expression in various cancer forms, its association with cancer prognosis, and its crucial roles in carcinogenesis and cancer immunity. In conclusion, this synthesized review integrates existing knowledge and novel insights on PCSK9, providing a holistic perspective on its transformative impact in reshaping therapeutic paradigms across various disorders. It emphasizes the clinical value and effect of PCSK9-iT, underscoring its potential in advancing the landscape of biomedical research and its capabilities in heralding new eras in personalized medicine.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
jiang完成签到,获得积分10
1秒前
小鹿发布了新的文献求助10
1秒前
1秒前
荷叶粥完成签到,获得积分10
2秒前
1234发布了新的文献求助10
2秒前
土豪的哑铃完成签到,获得积分10
2秒前
LiugQin完成签到,获得积分10
2秒前
3秒前
sxr完成签到,获得积分10
3秒前
li_xingyan发布了新的文献求助10
3秒前
3秒前
冷酷男人完成签到,获得积分10
4秒前
科研通AI6.4的应助被天空采纳,获得10
4秒前
阳光开朗大牛牛完成签到,获得积分10
4秒前
星空发布了新的文献求助10
4秒前
风清扬完成签到,获得积分0
4秒前
小小小先生的应助被mm采纳,获得10
4秒前
Yacfans完成签到 ,获得积分10
4秒前
顶刊刺客cc完成签到,获得积分10
5秒前
5秒前
深情安青的应助被adai007采纳,获得10
5秒前
6秒前
Su完成签到,获得积分10
6秒前
Luoyx完成签到,获得积分10
6秒前
xu完成签到,获得积分10
6秒前
橘子完成签到 ,获得积分10
6秒前
悬停之翼完成签到,获得积分10
6秒前
6秒前
乐观的驳完成签到,获得积分10
6秒前
沉夕完成签到,获得积分10
6秒前
cdercder的应助被元谷雪采纳,获得10
6秒前
落冰花完成签到 ,获得积分20
7秒前
小水蜜桃完成签到 ,获得积分10
7秒前
失物爱发布了新的文献求助10
7秒前
晚秋发布了新的文献求助10
7秒前
俊逸香岚完成签到,获得积分10
7秒前
7秒前
7秒前
爱岗敬业牛马人完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105